AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

Key Figures

Price target cut: $15 to $8 Single-session loss: over 37% Share price drop: $6.21 to $3.91 +5 more

8 metrics

Price target cut $15 to $8 Cantor target reduction on January 9, 2026 for AQST

Single-session loss over 37% Losses for AQST purchasers between June 16, 2025 and January 8, 2026

Share price drop $6.21 to $3.91 Reaction after FDA identified Anaphylm NDA deficiencies

Per-share loss $2.30 per share AQST share decline tied to FDA deficiency disclosure

PDUFA date January 31, 2026 Target FDA decision date for Anaphylm NDA referenced by management

Below cash scenario ~$1/sh Oppenheimer worst-case scenario for AQST shares

Potential delay length 12 to 15 months Oppenheimer comparison to prior FDA delays at SPRY and ASND

Lead plaintiff deadline May 4, 2026 Securities class action lead plaintiff filing deadline

Market Reality Check

Price: $4.27 Vol: Volume 1,680,645 is below...

normal vol

$4.27 Last Close

Volume Volume 1,680,645 is below the 20-day average of 2,393,206 (relative volume 0.7x). normal

Technical Shares at $4.27 are trading below the 200-day MA of $4.73 and 43.44% below the 52-week high.

Peers on Argus

AQST gained 1.67% while close peers showed mixed moves: ESPR -3.36%, ORGO -1.11%...

1 Up

AQST gained 1.67% while close peers showed mixed moves: ESPR -3.36%, ORGO -1.11%, SIGA -3.1%, AKBA +1.45%, EOLS +1.7%. This points to stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Inducement equity grants	Neutral	-2.1%	Inducement RSUs and stock options granted to new Chief Medical Officer.
Mar 04	Earnings and CRL update	Negative	-2.5%	Q4/FY2025 results with revenue growth but FDA Complete Response Letter for Anaphylm.
Feb 25	Investor conferences	Positive	+1.2%	Participation in multiple March investor conferences and related presentations.
Feb 24	Earnings date notice	Neutral	+3.0%	Announcement of Q4 2025 earnings release and investor conference call timing.
Feb 23	Healthcare conference	Positive	+0.5%	Oppenheimer healthcare conference presentation and investor one‑on‑one meetings.

Pattern Detected

Recent AQST news, including earnings and corporate updates, often saw modest single‑digit price reactions, with one divergence where equity awards coincided with a slight decline.

Recent Company History

Over recent months, Aquestive issued several corporate and investor updates, including conference participation and an earnings report on March 4, 2026 where Q4 revenue rose 10% to $13.0M and the company disclosed a Complete Response Letter for Anaphylm plus plans for a Type A meeting and NDA resubmission in Q3 2026, alongside guidance to ~$70M year‑end 2026 cash. Other releases covered investor conferences and inducement/compensation equity awards, which collectively produced modest, mostly aligned single‑day price moves.

Market Pulse Summary

This announcement highlights a securities lawsuit centered on AQST’s past FDA communications, analys...

Analysis

This announcement highlights a securities lawsuit centered on AQST’s past FDA communications, analyst target cuts from $15 to $8, and significant single‑session share losses after Anaphylm NDA deficiencies were disclosed. It underscores how expectations around the January 31, 2026 PDUFA date and potential CRL risk became central to the story. Investors following this development typically track ongoing FDA interactions, resubmission plans, class‑action timelines, and future analyst commentary when evaluating risk.

Key Terms

complete response letter, nda, pdufa date, citizen petition

4 terms

complete response letter regulatory

"the history of CRLs following similar letters increases the risk of a potential delay"

A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.

nda regulatory

"deficiencies in its Anaphylm NDA that precluded labeling discussions"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

pdufa date regulatory

"on track for FDA approval by the January 31, 2026 PDUFA date"

PDUFA date is the deadline the U.S. Food and Drug Administration sets to complete its review of a drug or biologic application and decide whether to approve it. Investors watch it like a court verdict date: the decision can unlock sales and growth if approved or sharply reduce expected value if denied, so markets often move significantly as the date approaches or when the outcome is announced.

citizen petition regulatory

"depending on the FDA's consideration of a Citizen Petition"

A citizen petition is a formal written request to a government regulator asking them to start, change, review, or stop a policy, approval, or enforcement action. Anyone—companies, competitors, consumer groups or individuals—can file one, and for investors it matters because a petition can trigger reviews or delays that act like a temporary “pause” on a product or market access, potentially affecting sales, valuation, and competitive position.

AI-generated analysis. Not financial advice.

Wall Street Reassessment: Analyst Opinion Evolution on AQST

NEW YORK, March 12, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who purchased AQST securities between June 16, 2025 and January 8, 2026 lost over 37% of their investment value in a single trading session. Find out if you qualify to recover your investment losses. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.

AQST shares fell from $6.21 to $3.91 per share, a loss of $2.30 per share, after Aquestive disclosed that the FDA had identified deficiencies in its Anaphylm NDA that precluded labeling discussions. The lead plaintiff deadline is May 4, 2026.

Initial Analyst Optimism

Throughout the Class Period, sell-side analysts covering AQST built their models around management's repeated assurances that Anaphylm was on track for FDA approval by the January 31, 2026 PDUFA date. The complaint recounts that the Company described its FDA interactions as routine, characterized the review process as progressing normally, and stated commercial launch preparations were underway for Q1 2026. Analysts set price targets and issued coverage reflecting these representations.

The Downgrades Begin

The January 9, 2026 disclosure triggered rapid reassessment across Wall Street:

• Cantor reduced its price target by 47%, from $15 to $8, citing the elevated risk of a Complete Response Letter
• Oppenheimer published a report stating that the FDA's communication was "a meaningful setback" and that the stock was "currently pricing in a CRL, the most likely scenario"
• Oppenheimer outlined three scenarios, with the worst case sending shares "below cash (~$1/sh)" depending on the FDA's consideration of a Citizen Petition
• Oppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delays

Execution Concerns on Wall Street

The analyst commentary reveals a critical disconnect. As alleged in the action, management portrayed the FDA review as entirely routine. On the November 6, 2025 earnings call, the Company described the review process by stating the different functions in the FDA were "doing their jobs, completing their checklists and asking us the questions you would expect." Yet within weeks, the FDA flagged deficiencies serious enough to halt labeling discussions entirely. Analysts had no basis to anticipate this outcome given the information provided.

Why Analyst Shifts Matter for Investors

"When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. The magnitude of the target price reductions here reflects how heavily the market relied on management's characterizations of the FDA review." — Joseph E. Levi, Esq.

The breadth and speed of the analyst downgrades underscore that the market treated management's statements about FDA progress as material. When those statements proved inconsistent with the FDA's actual findings, analysts and investors repriced AQST accordingly, causing substantial losses to Class Period purchasers.

Speak with an attorney about recovering your AQST losses or call (212) 363-7500.

LEAD PLAINTIFF DEADLINE: May 4, 2026

Levi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@SueWallSt.com

Tel: (888) SueWallSt

Fax: (212) 363-7171

View original content:https://www.prnewswire.com/news-releases/aqst-lawsuit-alleges-analyst-slashed-price-target---aquestive-therapeutics-inc-investors-face-losses-following-analyst-slashed-price-target-suewallst-302711889.html

SOURCE SueWallSt.com